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Abstract 
Neuromyelitis optica spectrum disorder is an inflammatory demyelinating disease that is 
largely sporadic. Familial disease has been reported in one or two generations, although its 
basis remains unknown. We report here three subjects meeting diagnostic criteria for 
NMOSD in one family: a father and son, and the maternal aunt of the father. Anticipation, of 
27 years, was apparent in transmission from father to son. Aquaporin-4 antibodies were 
observed in the aunt but not the father and son, nor in other family members. A putative 
pathogenic mutation in the NECL2 gene was not found in this pedigree. This first report of 
NMOSD in three generations of one family underlines the heterogeneity of familial NMOSD. 
 
Introduction 
Neuromyelitis optica spectrum disorder (NMOSD) describes inflammatory demyelinating 
disease of the nervous system characterized by optic neuritis and long segmental spinal 
cord injury. The disease may demonstrate a recurring-remitting course but with residual 
spinal cord demyelination and, in the majority of cases, serum aquaporin-4 (AQP4) 
antibodies which are considered to be pathogenic. Patients often have limb dysfunction, 
numbness and visual impairment. As there is variability in the presentation, imaging and 
laboratory findings indicating possible disease heterogeneity, consensus diagnostic criteria 
have recently been formulated for NMOSD (Wingerchuk et al., 2015). 
Occurrence of NMOSD is largely sporadic, although there have been reports of familial cases 
over one or two generations (Matiello et al., 2010).  The genetic basis of familial inheritance 
of NMOSD is unknown; case-control studies have reported associations with polymorphisms 
in a variety of genes including interleukin-17, HLA antigens and CD proteins as well as AQP4. 
Apart from AQP4 however, these have not been studied in familial cases, and AQP4 
polymorphisms have not yielded consistent findings of linkage with NMOSD from the few 
familial cases studied (Matiello et al., 2011).  However, a recent paper (Xu et al., 2018) has 
described a functional deletion variant of a candidate gene, the cellular adhesion molecule 
NECL2, in three members of one NMOSD family and in a proportion of sporadic cases but 
not in control subjects.  
We report here three cases of NMOSD over three generations of a Chinese family and 
investigate whether linkage with the previously-reported and potentially pathogenic NECL2 
mutation extends to this family. 
 
Methods 
All subjects had given written informed consent for this study, which was approved by Puer 
People’s Hospital Ethics Committee. 
Following the identification of two patients, father and son, with suspected NMOSD, who 
were related to a patient previously diagnosed with NMO, 11 genetically-related 
asymptomatic family members also had their serum AQP4 antibody status determined 
initially by ELISA and subsequently confirmed by cell-based assay. 
We developed a pyrosequencing method for determination of a nine-base deletion 
mutation in the NECL2 gene (rs770344177, c.1052_1060delCCACCACCA) (Xu et al., 2018). 
Following DNA extraction from blood samples, the sequence was amplified by PCR using 
primers, including a biotinylated reverse primer, as follows: Forward 
5’GTTGTGTTCAGCATTGTGGGT3’, Reverse [Btn]5’CTGGGATGTTTCTGAGGTCCTT3’ (Eurofins). 
PCR reactions were carried out with 20 ng of DNA using the PyroMark PCR kit in a final 
volume of 25 µl containing 12.5 µl 1x PyroMark PCR Master Mix, 2.5 µl 1x CoralLoad 
Concentrate, 1 µl of each primer in a final concentration of 0.05 µM, 8 µl RNase-free water. 
Amplification conditions were as follows: 95°C for 15 min, 45 cycles of 94°C for 30 s, 56°C for 
30 s and 72°C for 30 s, finally, 72°C for 10 min.  
The InDel analysis was determined with a PyroMark Q24 pyrosequencer (Qiagen UK) using 
15–20 µl PCR product and a sequencing primer 5'CACAACTATCCCTCCTCCCACAAC3’ 
(Eurofins). Pyrosequencing setup and data reading were conducted by PyroMark Q24 
2.0.6.20 software (Qiagen UK). Samples underwent PCR and pyrosequencing in duplicate; 
inconsistencies between samples were resolved following further repetition.  
 
Results 
Index case. A 34-year-old Chinese Han woman (Patient 1) in Yunnan, China, developed 
vision loss in her right eye in May 1999, subsequently with some deterioration in the left 
eye, having an expanded disability status scale (EDSS) score of 5. Five months later she had 
developed left limb weakness but could walk with assistance (EDSS: 7). Visual evoked 
potential and magnetic resonance imaging (MRI) of the brain and spinal cord were 
examined and she received a diagnosis of NMO. CSF analysis was normal other than slightly 
raised protein (0.5g/L). After dexamethasone treatment her symptoms improved but she 
had residual blurred vision in her right eye. Subsequently the patient had more than 10 
episodes of decreased visual acuity and limb weakness. Her binocular vision decreased 
gradually with the number of episodes. Further CSF analysis showed oligoclonal banding to 
be negative. MRI in 2011 showed no apparent brain abnormality but the spinal cord lesions 
exceeded 3 segments (Figure 1), and optic nerve injury was indicated in the visual evoked 
potential examination. The patient was prescribed methylprednisolone which alleviated the 
symptoms. There was no symptom exacerbation after prescription of azathioprine (100mg 
bid) in 2011. In 2009 she tested negative for anti-Sjögren’s-syndrome-related antigen A 
(anti-SSA) and Anti-SSB. In 2018 she tested positive for serum AQP4 antibodies and negative 
for MOG antibodies. 
Patient 2, the son of an older sister of patient 1, first developed symptoms of lower 
extremity weakness and urinary incontinence in November 2008 at the age of 38. 
Symptoms gradually worsened over 25 days resulting in complete paralysis of the lower 
limbs (EDSS: 8.5). MRI showed a normal brain while the spinal cord exhibited a lesion over 5 
segments and he was diagnosed with acute myelitis. CSF analysis showed increased white 
cell count and raised protein (0.86g/L). He was prescribed methylprednisolone; in the 
following 3 years there were six episodes of disease recurrence, mainly with bilateral lower 
limb weakness (EDSS:  3-6). after initiating treatment with azathioprine (100mg bid) in 2011 
there were only two further episodes. CSF oligoclonal banding was negative. He was 
diagnosed as having NMOSD and, in 2018, symptoms of vision loss began to appear. He 
tested positive for anti-SSA in 2008 and 2017. Serum AQP4 antibody tested negative in 2018 
when MRI was also reviewed (shown in Figure 2) and serum MOG antibodies tested 
negative in 2018. 
Patient 3, the son of patient 2, developed numbness in both lower extremities in May 2014 
at the age of 11. MRI examination identified a cervical spinal cord lesion which extended 
over 3 segments (Figure 3) with normal brain imaging; routine CSF analysis was normal and 
oligoclonal banding was negative. He was diagnosed with NMOSD and received treatment 
with gamma globulin. In 2017 he was free of symptoms and tested negative for anti-SSA and 
Anti-SSB; in 2018 he tested negative for serum AQP4 antibodies and in 2019 serum MOG 
antibodies tested negative. 
Eleven other members of the family tested negative for serum AQP4 antibody (Figure 4). 
The three patients and these family members (excepting the children of patient 2’s eldest 
brother) underwent genotyping for the NECL2 polymorphism rs770344177 and were all 
unequivocally identified as homozygous wild-type, i.e. free of the deletion mutation. 
 
Discussion 
The occurrence of familial NMO is estimated to be approximately 3% of cases (Matiello et 
al., 2010; Papais-Alvarenga et al., 2015) and that for NMOSD is likely to be similar. Reported 
familial cases occur primarily in first-degree relatives and in almost all reports only two 
patients are identified in each pedigree. Genetic anticipation is apparent in several of these 
families with parent-child age differences at onset varying from 23-42 years (Kavoussi et al., 
2015).  
As far as we are aware, this is the first report of a family with NMOSD represented in each of 
three generations, although it is notable that the oldest case is a second-degree relative of 
the patient in the following generation. We cannot rule out the occurrence of NMOSD in the 
aunt of patient 2 being a sporadic case rather than a genetic relationship, particularly given 
the difference in AQP4 immunostatus, although this seems unlikely. It is notable in this 
respect that Papais-Alvarenga et al. (2015) identified two sisters with NMOSD who were 
discordant for anti-AQP4, while five of the 12 families reported by Matiello et al. (2010) 
were also heterogeneous in AQP4 status.  
There is genetic anticipation in transmission from father to son with a difference in age of 
onset of 27 years.  The relative rarity of reports of NMOSD over three generations may 
reflect this genetic anticipation (i.e. death may precede disease onset in the first generation) 
and indicates that the reported proportion of hereditary disease may be an underestimate. 
Variability of disease onset age in siblings is generally small although 16 years difference 
between two sisters has been observed previously (Matiello et al., 2010). A large difference 
in onset age is implied between patient 1 and her unaffected older sister, the presumed 
obligate carrier. 
A genetic mutation with strong evidence for association with familial NMOSD, a coding 
region deletion in NECL2, has been observed in two daughters with NMOSD and an 
asymptomatic mother, and in 5.7% of sporadic cases, but is absent in 212 control subjects 
(Xu et al., 2018).  However, the patients and their extended family studied here did not 
exhibit this potentially pathogenic deletion mutation. We can conclude that this specific 
deletion is not present in all familial NMOSD cases, underlining the genetic heterogeneity of 
familial NMOSD (Matiello et al., 2011), although we cannot rule out association of familial 
disease with other mutations of the NECL2 gene or elsewhere in the genome. 
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